|Day Low/High||291.30 / 301.34|
|52 Wk Low/High||223.02 / 338.51|
The S&P 500 and Nasdaq extend their declines on Wednesday afternoon as crude oil resumes its slide after briefly touching the flatline.
More about Vertex' Debbie Downer gene, Biogen's Alzheimer's spin and Sarepta caught in drug launch purgatory.
Stocks pull back from losses on Wednesday as crude oil recovers, though Apple continues to sour sentiment.
Stock futures turn lower for another day on Wednesday after Apple, the biggest weight on the S&P 500, posts a so-so quarter.
Biogen (BIIB) posted better-than-anticipated results for the third quarter this morning.
Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016 financial results, including: Total revenues of $3.
A study of analyst recommendations at the major brokerages shows that Biogen Inc is the #45 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.
On Wednesday Biogen (BIIB) is projected to post third-quarter earnings and revenue that have improved from a year ago.
Tech giants, Big Pharma and insurers are all angling to profit from the $3 trillion-plus U.S. healthcare market.
Wall Street enters the thick of earnings reporting in week three of the season with heavyweights Apple and Alphabet on tap.
Pfizer may not be the best investment in coming months, as doubts surface about the company's near-term prospects in the absence of M&A.
New data from the clinical program for nusinersen, an investigational treatment for spinal muscular atrophy (SMA), were presented by Biogen (NASDAQ: BIIB) and Ionis Pharmaceuticals (NASDAQ: IONS) in the late-breaking...
Here's a technical look at how to trade some of the most active stocks on the market right now.
Biogen (NASDAQ: BIIB) and Ionis (NASDAQ:IONS) today announced that Biogen has completed the rolling submission of a New Drug Application (NDA) to the U.
Stocks in the health care sector are vulnerable to declines following the 2016 presidential election, according to S&P analyst Scott Kessler.
The company could divest non-core assets after Starboard Value revealed a 4.6% stake.
What to do with $40 billion? That is the question facing Allergan (AGN). One biotechnology stock which stands out as a potential target for Allergan is Applied Genetic Technologies (AGTC).
A new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with ZINBRYTA TM (daclizumab) achieved no evidence of disease activity (NEDA) compared to those taking...
Biogen Inc. (NASDAQ:BIIB) today announced it will report third quarter 2016 financial results on Wednesday, October 26, 2016, before the financial markets open.
Stocks lose highs by mid-afternoon Wednesday as a selloff in crude resumes.
U.S. stocks bounced around in the green in far more stable trading following three days of extreme swings.
Stocks add to slight gains on Wednesday as Wall Street stabilizes after three days of extreme swings.
Biogen (BIIB) reported Wednesday that Tecfidera, its multiple sclerosis treatment, had positive results in recent clinical and real world trials.
New real-world and clinical evidence demonstrates that TECFIDERA ® (dimethyl fumarate) consistently delivered strong, sustained efficacy in newly-diagnosed and previously treated patients with relapsing-remitting...
New research collected from more than 16,000 multiple sclerosis (MS) patients across Europe, in the largest study to capture the widespread impact of the disease, along with updated clinical findings from the company's...
Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.